Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Burkitt Lymphoma 2Recurrence 1

Interventions

Magnetic Resonance Spectroscopy 271Specimen Handling 266pembrolizumab 233Cyclophosphamide 219Radiotherapy 208Nivolumab 169Cisplatin 165Biopsy 152Carboplatin 145Radiosurgery 131fludarabine 125Blood Specimen Collection 120Gemcitabine 113Paclitaxel 109Surveys and Questionnaires 108Standard of Care 106venetoclax 97Dexamethasone 95Bevacizumab 93Radiation 87Rituximab 83Capecitabine 81Cytarabine 80Oxaliplatin 77Drug Therapy 76Doxorubicin 75Ipilimumab 74durvalumab 73fludarabine phosphate 70atezolizumab 69

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × CVAD protocol × 90 days × Clear all
NCT07564453 2026-05-04

FLOW

The First Affiliated Hospital of Soochow University

Phase 2 Recruiting
101 enrolled
Lymphoid

Burkitt Lymphoma

NCT06287229 2026-04-24

Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
40 enrolled
Lymphoid

Burkitt Lymphoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡